AMPH vs RMD: fair value comparison
Amphastar Pharmaceuticals, Inc. and ResMed Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, RMD currently sits closer to the top of our discount ranking. RMD carries the stronger quality grade. AMPH carries the stronger momentum grade.
| AMPH | RMD | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $22.96 | $218.27 |
| 12-month range | $18.42–$27.92 | $186.44–$257.39 |
| Sector rank | #26 of 113 Healthcare | #25 of 113 Healthcare |
| Quality grade | B | A |
| Momentum grade | A | B |
| Leverage | Moderate | Low |
| Margin trend | Contracting | Expanding |
| Revenue growth | Modest | Strong |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The lower-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: AMPH fair value analysis · RMD fair value analysis